Page last updated: 2024-08-23

glucaric acid and Kidney Failure, Chronic

glucaric acid has been researched along with Kidney Failure, Chronic in 76 studies

Research

Studies (76)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's7 (9.21)18.2507
2000's45 (59.21)29.6817
2010's24 (31.58)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Abrams, G; Adolfsson, E; Agarwal, PK; Akkan, AG; Al Alhareth, NS; Alves, VGL; Armentano, R; Bahroos, E; Baig, M; Baldridge, KK; Barman, S; Bartolucci, C; Basit, A; Bertoli, SV; Bian, L; Bigatti, G; Bobenko, AI; Boix, PP; Bokulic, T; Bolink, HJ; Borowiec, J; Bulski, W; Burciaga, J; Butt, NS; Cai, AL; Campos, AM; Cao, G; Cao, Y; Čapo, I; Caruso, ML; Chao, CT; Cheatum, CM; Chelminski, K; Chen, AJW; Chen, C; Chen, CH; Chen, D; Chen, G; Chen, H; Chen, LH; Chen, R; Chen, RX; Chen, X; Cherdtrakulkiat, R; Chirvony, VS; Cho, JG; Chu, K; Ciurlino, D; Coletta, S; Contaldo, G; Crispi, F; Cui, JF; D'Esposito, M; de Biase, S; Demir, B; Deng, W; Deng, Z; Di Pinto, F; Domenech-Ximenos, B; Dong, G; Drácz, L; Du, XJ; Duan, LJ; Duan, Y; Ekendahl, D; Fan, W; Fang, L; Feng, C; Followill, DS; Foreman, SC; Fortunato, G; Frew, R; Fu, M; Gaál, V; Ganzevoort, W; Gao, DM; Gao, X; Gao, ZW; Garcia-Alvarez, A; Garza, MS; Gauthier, L; Gazzaz, ZJ; Ge, RS; Geng, Y; Genovesi, S; Geoffroy, V; Georg, D; Gigli, GL; Gong, J; Gong, Q; Groeneveld, J; Guerra, V; Guo, Q; Guo, X; Güttinger, R; Guyo, U; Haldar, J; Han, DS; Han, S; Hao, W; Hayman, A; He, D; Heidari, A; Heller, S; Ho, CT; Ho, SL; Hong, SN; Hou, YJ; Hu, D; Hu, X; Hu, ZY; Huang, JW; Huang, KC; Huang, Q; Huang, T; Hwang, JK; Izewska, J; Jablonski, CL; Jameel, T; Jeong, HK; Ji, J; Jia, Z; Jiang, W; Jiang, Y; Kalumpha, M; Kang, JH; Kazantsev, P; Kazemier, BM; Kebede, B; Khan, SA; Kiss, J; Kohen, A; Kolbenheyer, E; Konai, MM; Koniarova, I; Kornblith, E; Krawetz, RJ; Kreouzis, T; Kry, SF; Laepple, T; Lalošević, D; Lan, Y; Lawung, R; Lechner, W; Lee, KH; Lee, YH; Leonard, C; Li, C; Li, CF; Li, CM; Li, F; Li, J; Li, L; Li, S; Li, X; Li, Y; Li, YB; Li, Z; Liang, C; Lin, J; Lin, XH; Ling, M; Link, TM; Liu, HH; Liu, J; Liu, M; Liu, W; Liu, YP; Lou, H; Lu, G; Lu, M; Lun, SM; Ma, Z; Mackensen, A; Majumdar, S; Martineau, C; Martínez-Pastor, JP; McQuaid, JR; Mehrabian, H; Meng, Y; Miao, T; Miljković, D; Mo, J; Mohamed, HSH; Mohtadi, M; Mol, BWJ; Moosavi, L; Mosdósi, B; Nabu, S; Nava, E; Ni, L; Novakovic-Agopian, T; Nyamunda, BC; Nyul, Z; Önal, B; Özen, D; Özyazgan, S; Pajkrt, E; Palazon, F; Park, HW; Patai, Á; Patai, ÁV; Patzke, GR; Payette, G; Pedoia, V; Peelen, MJCS; Pellitteri, G; Peng, J; Perea, RJ; Pérez-Del-Rey, D; Popović, DJ; Popović, JK; Popović, KJ; Posecion, L; Povall, J; Prachayasittikul, S; Prachayasittikul, V; Prat-González, S; Qi, B; Qu, B; Rakshit, S; Ravelli, ACJ; Ren, ZG; Rivera, SM; Salo, P; Samaddar, S; Samper, JLA; Samy El Gendy, NM; Schmitt, N; Sekerbayev, KS; Sepúlveda-Martínez, Á; Sessolo, M; Severi, S; Sha, Y; Shen, FF; Shen, X; Shen, Y; Singh, P; Sinthupoom, N; Siri, S; Sitges, M; Slovak, JE; Solymosi, N; Song, H; Song, J; Song, M; Spingler, B; Stewart, I; Su, BL; Su, JF; Suming, L; Sun, JX; Tantimavanich, S; Tashkandi, JM; Taurbayev, TI; Tedgren, AC; Tenhunen, M; Thwaites, DI; Tibrewala, R; Tomsejm, M; Triana, CA; Vakira, FM; Valdez, M; Valente, M; Valentini, AM; Van de Winckel, A; van der Lee, R; Varga, F; Varga, M; Villarino, NF; Villemur, R; Vinatha, SP; Vincenti, A; Voskamp, BJ; Wang, B; Wang, C; Wang, H; Wang, HT; Wang, J; Wang, M; Wang, N; Wang, NC; Wang, Q; Wang, S; Wang, X; Wang, Y; Wang, Z; Wen, N; Wesolowska, P; Willis, M; Wu, C; Wu, D; Wu, L; Wu, X; Wu, Z; Xia, JM; Xia, X; Xia, Y; Xiao, J; Xiao, Y; Xie, CL; Xie, LM; Xie, S; Xing, Z; Xu, C; Xu, J; Yan, D; Yan, K; Yang, S; Yang, X; Yang, XW; Ye, M; Yin, Z; Yoon, N; Yoon, Y; Yu, H; Yu, K; Yu, ZY; Zhang, B; Zhang, GY; Zhang, H; Zhang, J; Zhang, M; Zhang, Q; Zhang, S; Zhang, W; Zhang, X; Zhang, Y; Zhang, YW; Zhang, Z; Zhao, D; Zhao, F; Zhao, P; Zhao, W; Zhao, Z; Zheng, C; Zhi, D; Zhou, C; Zhou, FY; Zhu, D; Zhu, J; Zhu, Q; Zinyama, NP; Zou, M; Zou, Z1
Batycky, A; Bernard, K; Dahl, NV; Li, Z; Macdougall, IC; Strauss, WE1
Imai, N; Shibagaki, Y; Taki, Y1
Coll, E; Corredor, ZF; Marcos, R; Pastor, S; Rodríguez-Ribera, L; Stoyanova, E1
Münch, HG; Potthoff, SA1
Mekic, M; Musanovic, A; Trnacevic, S1
Airy, M; Brookhart, MA; Chang, TI; Ding, VY; Goldstein, BA; Mandayam, S; Mitani, AA; Winkelmayer, WC1
Amato, C; Barbieri, C; Bellocchio, F; Bolzoni, E; Canaud, B; Cattinelli, I; Gatti, E; Macdougall, IC; Mari, F; Martin, JD; Stopper, A; Stuard, S1
Cebrián, C; Deira, J; Fernández-Pereira, L; Gómez-Martino, JR; González-Sanchidrián, S; Jiménez, M; Marín, J; Polanco, S; Tabernero, J1
Coyne, DW; Daloul, R; Pandey, R1
Berger, SP; Daha, MR; de Vlaam, TP; Franssen, CF; Gaillard, CA; Gaya da Costa, M; Hempel, JC; Poppelaars, F; Seelen, MA1
Airy, M; Brookhart, MA; Chang, TI; Ding, VY; Fishbane, S; Goldstein, BA; Mandayam, S; Mitani, AA; Winkelmayer, WC1
Anirban, G; Gupta, KL; Jha, V; Kohli, HS; Sakhuja, V1
Bailey, G; Cropper, L; Mostafa, S; Pugh-Clarke, K; Tagboto, S; Turner, J1
Bolaños, L; González-Juanatey, C; Ranero, R; Testa, A1
Collins, AJ; Foley, RN; Gilbertson, DT; Ibrahim, HN; Zhang, R1
Lorch, JA; Pollak, VE; Satwah, S; Shukla, R1
Bruguera, J; Cladellas, M; Comín-Colet, J; Rizzo, M; Ruiz, S; Torres, A1
Andreoli, MC; Carneiro, FD; Espósito, BP; Guimarães-Souza, NK; Mallet, AC; Matos, AC; Rangel, EB; Santos, BF1
Fernández-Gallego, J; Martín, MA; Sujan, S; Vega, E1
Bhandari, S; Chinnappa, S1
Hojs, N; Malovrh, M; Premru, V1
Fenwick, S; Peebles, G1
Atalay, H; Guney, I; Kaya, E; Solak, Y; Turk, S; Turkmen, K1
Fujii, H; Fujimori, A; Fukagawa, M; Goto, S; Hasegawa, H; Komaba, H; Nishi, S; Nishioka, M; Takeda, Y; Umezu, M1
Conner, TA; McQuade, C; Olp, J; Pai, AB1
Gollapudi, S; Hassanzadeh, T; Ichii, H; Masuda, Y; Saffarian, M; Vaziri, ND1
Bradbury, BD; Brookhart, MA; Freburger, JK; Kshirsagar, AV; Ng, LJ1
Chen, J; Chen, X; Cheng, M; Peng, Y; Yang, L; Yin, L1
Benmaadi, A; Bounhiol, C; Cohen, Y; Couprie, R; Dahan, H; Drahi, G; Griuncelli, M; Janklewicz, P; Loridon, C; Machado, G; Rostoker, G; Roy, M1
Baruch, R; Blum, M; Iaina, A; Keren, G; Schwartz, D; Shaked, M; Sheps, D; Silverberg, DS; Steinbruch, S; Tchebiner, J; Wexler, D; Yachnin, T; Zubkov, A2
Agarwal, R; Coyne, DW; Dahl, N; Folkert, VW; Michael, B; Myirski, P; Warnock, DG1
Calişkan, S; Camsari, T; Cavdar, C; Celik, A; Onvural, B; Sifil, A; Temiz, A; Yeniçerioğlu, Y1
Albarracín, C; Fanlo, B; Junquera, E; Rodríguez Palomares, JR1
Cohen, G; Deicher, R; Hörl, WH; Müllner, M; Ziai, F1
Avram, MM; Blaustein, DA; Chattopadhyay, J; Daoui, R; Gadh, R; Schwenk, MH; Singh, H1
Folkert, VW1
Blum, M; Iaina, A; Schwartz, D; Silverberg, D; Wexler, D1
Aronoff, GR; Bennett, WM; Blumenthal, S; Charytan, C; Pennell, JP; Reed, J; Rothstein, M; Strom, J; Van Wyck, D; Wolfe, A; Yee, J1
Bagdatoglu, O; Bali, M; Dhondt, AW; Guz, G; Kavutcu, M; Reis, KA; Sahinarslan, A; Sindel, S; Yalçin, R1
Abe, R; Horiuchi, T; Ogi, M; Wakabayashi, M; Wakabayashi, T1
El-Agroudy, A; El-Husseini, A; Hassan, N; Khalil, A; Sabry, A; Salem, A; Sheashaa, H; Sobh, M1
Erturk, S; Keven, K; Kutlay, S; Nergizoglu, G1
Collins, AJ; Obrador, GT; Roberts, TL; St Peter, WL1
Barut, Y; Eres, M; Gürsu, RU; Murat, B; Ozdemir, A; Selamet, U; Yalinbaş, B1
Hörl, WH; Sengölge, G; Sunder-Plassmann, G1
Födinger, M; Hörl, WH; Mittermayer, F; Puttinger, H; Schaller, G; Scheiber-Mojdehkar, B; Sunder-Plassmann, G; Vychytil, A; Wolzt, M1
Anbu, AT; Bradbury, MG; Kemp, T; O'donnell, K; Smith, PA1
Agarwal, R2
Raja, R; Rizkala, AR; Sirken, G1
Boyd, AV; Harford, A; McQuade, CR; Norenberg, JP; Pai, AB; Zager, PG1
Camps, J; Ferré, N; Joven, J; Mackness, B; Mackness, M; Marcas, L; Marsillach, J; Martínez-Vea, A1
Das, J; George, P; Itty, C; Pawar, B1
Deveci, M; Oymak, O; Sari, I; Sav, T; Sipahioglu, MH; Tokgoz, B; Utas, C1
Vikrant, S1
Charytan, C; Reed, J; Yee, J1
Grzegorzewska, AE1
Grekas, DM; Makedou, A; Makedou, K; Malindretos, P; Raptis, V; Rudenco, I; Sarafidis, PA1
Li, H; Wang, SX1
Blum, M; Frank, N; Iaina, A; Kaplan, E; Levi, BA; Peer, G; Silverberg, DS; Steinbruch, S1
Blum, M; Iaina, A; Kaplan, E; Peer, G; Silverberg, DS1
Hörl, WH; Sunder-Plassmann, G2
Akcicek, F; Atabay, G; Basci, A; Celik, A; Cirit, M; Ok, E; Ozkahya, M; Toz, H; Unsal, A1
Andrade, S; Colaço, S; Oliveira, C; Ponce, P; Santos, JP; Silva, J; Ventura, H1
Claris, O; Picaud, JC; Putet, G; Salle, BL1
Bailie, GR; Johnson, CA; Mason, NA1
Descombes, E; Fellay, G1
Grönhagen-Riska, C; Parkkinen, J; Peltonen, S; Rosenlöf, K; von Bonsdorff, L1
Al-Saloum, M; Charytan, C; Gagnon, S; Hafeez, T; Levin, N; Van Wyck, DB1
Agbaria, Z; Baruch, R; Blum, M; Deutsch, V; Iaina, A; Irony, M; Schwartz, D; Silverberg, DS; Steinbruch, S; Yachnin, T1
Gosriwatana, I; Hider, RC; Kersting, S; Kooistra, MP; Lu, S; Marx, JJ; Nijhoff-Schutte, J1
Eran, A; Harmankaya, O1
Hanson, SY; Johnson, AC; Wasse, H; Zager, RA1

Reviews

8 review(s) available for glucaric acid and Kidney Failure, Chronic

ArticleYear
    Proceedings. Mathematical, physical, and engineering sciences, 2019, Volume: 475, Issue:2227

    Topics: Acetylcholine; Acinetobacter baumannii; Actinobacteria; Action Potentials; Adalimumab; Adaptation, Physiological; Adipates; Administration, Oral; Adolescent; Adrenal Glands; Adsorption; Adult; Aged; Aged, 80 and over; Aging; AIDS-Related Opportunistic Infections; Aldosterone; Amino Acids; Ammonia; Amoxicillin; AMP-Activated Protein Kinases; Animals; Antacids; Anti-Bacterial Agents; Antineoplastic Agents; Antirheumatic Agents; Apgar Score; Area Under Curve; ARNTL Transcription Factors; Arterial Pressure; Arthritis, Juvenile; Athletes; Attention; Biodegradation, Environmental; Biofilms; Biofuels; Biological Therapy; Biomass; Biomimetic Materials; Bioreactors; Birth Weight; Bismuth; Blood Flow Velocity; Bone and Bones; Brain Injuries, Traumatic; Calcium; Calcium Channels; Capsaicin; Carbon; Carcinoma, Hepatocellular; Cardiomegaly, Exercise-Induced; Cartilage; Cartilage, Articular; Case-Control Studies; Catalysis; Cats; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Death; Cell Differentiation; Cell Line, Tumor; Cell Membrane; Charcoal; Chemokine CCL2; Child; Child, Preschool; Chondrogenesis; Chronic Disease; Circadian Clocks; Circadian Rhythm Signaling Peptides and Proteins; Clarithromycin; Coccidioides; Coccidioidomycosis; Cognitive Behavioral Therapy; Coinfection; Color; Coloring Agents; Computer Simulation; Computers, Molecular; Consensus; Corticosterone; Cyclic AMP Response Element-Binding Protein; Cytochrome P-450 Enzyme System; Death, Sudden, Cardiac; Density Functional Theory; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Dialysis Solutions; Disease Models, Animal; Dogs; Dopamine Agonists; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Drug Resistance, Bacterial; Drug Therapy, Combination; Electrocardiography; Electrocardiography, Ambulatory; Electrolytes; Endocardium; Endocrine Disruptors; Endocytosis; Endoscopy, Gastrointestinal; Escherichia coli Proteins; Esters; Evolution, Molecular; Executive Function; Feasibility Studies; Female; Ferric Compounds; Fluorescence; Fluorescent Dyes; Fluorine Radioisotopes; Frailty; Free Radical Scavengers; Gabapentin; Geriatric Assessment; Glucaric Acid; Glucocorticoids; Glucose; Glucose Metabolism Disorders; Halogenated Diphenyl Ethers; Heart Rate; Heart Ventricles; HEK293 Cells; Helicobacter Infections; Helicobacter pylori; Hep G2 Cells; Hepatocytes; Humans; Hungary; Hydrogen Sulfide; Hydrogen-Ion Concentration; Immunologic Factors; Immunomodulation; Immunosuppressive Agents; Independent Living; Indocyanine Green; Infant; Infant Formula; Infant Mortality; Infant, Newborn; Infant, Newborn, Diseases; Inflorescence; Insulin Resistance; Insulins; International Agencies; Iron; Isotonic Solutions; Kidney Failure, Chronic; Kinetics; Lactones; Leukocytes, Mononuclear; Liver Neoplasms; Macular Edema; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Magnetosomes; Male; Medical Audit; Mesenchymal Stem Cells; Metabolic Syndrome; Metformin; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Nude; Middle Aged; Molecular Conformation; Molecular Targeted Therapy; Motor Activity; Multiple Sclerosis; Mycophenolic Acid; Netherlands; Neuropsychological Tests; Nuclear Energy; Organs at Risk; Osteoarthritis; Osteoarthritis, Hip; Oxidation-Reduction; Palladium; Pericardium; Perinatal Death; Peritoneal Dialysis; Phantoms, Imaging; Pharmaceutical Preparations; Phospholipids; Phosphorylation; Physical Conditioning, Human; Physical Endurance; Pilot Projects; Polyketides; Polymers; Positron-Emission Tomography; Postoperative Period; Potassium; Powders; Pramipexole; Predictive Value of Tests; Pregabalin; Pregnancy; Pregnancy Outcome; Protein Structure, Secondary; Proton Pump Inhibitors; Puberty; Pulmonary Circulation; Quality Assurance, Health Care; Quantum Dots; Radiometry; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Intensity-Modulated; Rats, Sprague-Dawley; Receptors, CCR2; Receptors, Transferrin; Regeneration; Registries; Renal Insufficiency, Chronic; Reproducibility of Results; Research Design; Restless Legs Syndrome; Retina; Retinoid X Receptor alpha; Retrospective Studies; Rhenium; Risk Factors; RNA, Messenger; Severity of Illness Index; Sex Factors; Sodium; Sodium Fluoride; Solvents; Spectrometry, Fluorescence; Spectroscopy, Fourier Transform Infrared; Stereoisomerism; Stroke; Structure-Activity Relationship; Tachycardia, Ventricular; Tetracycline; Tetrahydrofolate Dehydrogenase; Tetrahydronaphthalenes; Thermodynamics; Thiophenes; Time Factors; Tinidazole; Tomography, Optical Coherence; Tomography, X-Ray Computed; Topiramate; Toxoplasma; Toxoplasmosis, Cerebral; Transferrin; Treatment Outcome; Up-Regulation; Upper Extremity; Uremia; Uveitis; Vascular Remodeling; Ventricular Fibrillation; Ventricular Function, Left; Ventricular Function, Right; Ventricular Remodeling; Verapamil; Veterans; Visual Acuity; Vitrectomy; Water Pollutants, Chemical; Zea mays; Zirconium

2019
[Safety aspects of parenteral iron supplementation therapies in patients with chronic kidney disease].
    Deutsche medizinische Wochenschrift (1946), 2013, Volume: 138, Issue:24

    Topics: Administration, Oral; Anaphylaxis; Anemia, Iron-Deficiency; Disaccharides; Ferric Compounds; Ferric Oxide, Saccharated; Ferrosoferric Oxide; Glucaric Acid; Humans; Infusions, Intravenous; Iron Compounds; Iron-Dextran Complex; Kidney Failure, Chronic; Maltose; Oxidative Stress; Renal Dialysis

2013
Iron Treatment Strategies in Dialysis-Dependent CKD.
    Seminars in nephrology, 2016, Volume: 36, Issue:2

    Topics: Administration, Intravenous; Anemia, Iron-Deficiency; Disaccharides; Ferric Compounds; Ferric Oxide, Saccharated; Ferritins; Ferrosoferric Oxide; Glucaric Acid; Hematinics; Hemoglobins; Humans; Iron Compounds; Iron-Dextran Complex; Kidney Failure, Chronic; Maltose; Renal Dialysis; Transferrin

2016
Intravenous iron therapy: well-tolerated, yet not harmless.
    European journal of clinical investigation, 2005, Volume: 35 Suppl 3

    Topics: Anemia; Cytokines; Endothelial Cells; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Gluconates; Hematinics; Humans; Injections, Intravenous; Iron; Iron-Dextran Complex; Kidney Failure, Chronic; Neutrophils

2005
[Administration of iron-containing drugs in non-dialyzed patients with chronic kidney disease].
    Polskie Archiwum Medycyny Wewnetrznej, 2007, Volume: 117, Issue:4

    Topics: Administration, Oral; Anemia, Iron-Deficiency; Diet, Protein-Restricted; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Humans; Infusions, Intravenous; Iron; Iron Metabolism Disorders; Iron, Dietary; Kidney Failure, Chronic; Risk Factors; Sex Distribution; Treatment Outcome

2007
Safety aspects of parenteral iron in patients with end-stage renal disease.
    Drug safety, 1997, Volume: 17, Issue:4

    Topics: Anemia, Iron-Deficiency; Citric Acid; Drug Combinations; Drug Monitoring; Erythropoietin; Ferric Compounds; Ferric Oxide, Saccharated; Ferrous Compounds; Glucaric Acid; Humans; Infusions, Intravenous; Injections, Intravenous; Iron Compounds; Iron Overload; Iron-Dextran Complex; Kidney Failure, Chronic; Sorbitol

1997
[Iron supplementation in preterm infants treated with erythropoietin].
    Archives de pediatrie : organe officiel de la Societe francaise de pediatrie, 1999, Volume: 6, Issue:6

    Topics: Adult; Dietary Supplements; Erythropoietin; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Hematinics; Humans; Infant, Newborn; Infant, Premature; Infusions, Intravenous; Kidney Failure, Chronic; Recombinant Proteins

1999
Parenteral iron use in the management of anemia in end-stage renal disease patients.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 2000, Volume: 35, Issue:1

    Topics: Anemia, Iron-Deficiency; Erythropoietin; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Humans; Infusions, Intravenous; Iron-Dextran Complex; Kidney Failure, Chronic; Peritoneal Dialysis; Recombinant Proteins; Renal Dialysis

2000

Trials

29 trial(s) available for glucaric acid and Kidney Failure, Chronic

ArticleYear
The Ferumoxytol for Anemia of CKD Trial (FACT)-a randomized controlled trial of repeated doses of ferumoxytol or iron sucrose in patients on hemodialysis: background and rationale.
    BMC nephrology, 2017, 04-03, Volume: 18, Issue:1

    Topics: Administration, Intravenous; Anemia, Iron-Deficiency; Ferric Compounds; Ferric Oxide, Saccharated; Ferrosoferric Oxide; Glucaric Acid; Heart; Hematinics; Humans; Kidney Failure, Chronic; Liver; Magnetic Resonance Imaging; Pancreas; Renal Dialysis

2017
Very low doses of direct intravenous iron in each session as maintenance therapy in hemodialysis patients.
    Renal failure, 2016, Volume: 38, Issue:7

    Topics: Administration, Intravenous; Anemia, Iron-Deficiency; Biomarkers; C-Reactive Protein; Erythropoiesis; Female; Ferric Compounds; Ferric Oxide, Saccharated; Ferritins; Glucaric Acid; Hematinics; Hemoglobins; Hepcidins; Humans; Kidney Failure, Chronic; Maintenance Chemotherapy; Male; Renal Dialysis; Reticulocyte Count; Reticulocytes; Transferrin

2016
The comparative safety of various intravenous iron preparations in chronic kidney disease patients.
    Renal failure, 2008, Volume: 30, Issue:6

    Topics: Adult; Age Factors; Analysis of Variance; Anemia, Iron-Deficiency; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Ferric Compounds; Ferric Oxide, Saccharated; Follow-Up Studies; Glucaric Acid; Humans; Infusions, Intravenous; Iron-Dextran Complex; Kidney Failure, Chronic; Logistic Models; Male; Middle Aged; Predictive Value of Tests; Probability; Renal Dialysis; Risk Assessment; Severity of Illness Index; Sex Factors; Treatment Outcome

2008
Intravenous iron in chronic kidney disease: haemoglobin change shortly after treatment of patients neither on dialysis nor on erythropoietin.
    Journal of renal care, 2008, Volume: 34, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Anemia, Iron-Deficiency; Cost-Benefit Analysis; Drug Administration Schedule; Drug Monitoring; Erythropoietin; Female; Ferric Compounds; Ferric Oxide, Saccharated; Ferritins; Glomerular Filtration Rate; Glucaric Acid; Hemoglobins; Humans; Infusions, Intravenous; Kidney Failure, Chronic; Male; Middle Aged; Renal Dialysis; Severity of Illness Index; Sucrose; Transferrin; Treatment Outcome

2008
Effect of intravenous vitamin C on cytokine activation and oxidative stress in end-stage renal disease patients receiving intravenous iron sucrose.
    Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine, 2012, Volume: 25, Issue:5

    Topics: Adult; Ascorbic Acid; Cross-Over Studies; Cytokines; Epoetin Alfa; Erythropoietin; F2-Isoprostanes; Female; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Humans; Infusions, Intravenous; Kidney Failure, Chronic; Lipid Peroxidation; Male; Membrane Potential, Mitochondrial; Middle Aged; Oxidative Stress; Prospective Studies; Reactive Oxygen Species; Recombinant Proteins; Systems Biology

2012
[Multi-frequency low-dose intravenous iron on oxidative stress in maintenance hemodialysis patients].
    Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences, 2012, Volume: 37, Issue:8

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anemia; Female; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Humans; Injections, Intravenous; Kidney Failure, Chronic; Male; Middle Aged; Oxidative Stress; Renal Dialysis; Sucrose; Young Adult

2012
Hemodialysis-associated hemosiderosis in the era of erythropoiesis-stimulating agents: a MRI study.
    The American journal of medicine, 2012, Volume: 125, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Anemia; Biomarkers; Cross-Sectional Studies; Drug Therapy, Combination; Female; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Hematinics; Hemosiderosis; Humans; Infusions, Intravenous; Iron; Kidney Failure, Chronic; Liver; Logistic Models; Longitudinal Studies; Magnetic Resonance Imaging; Male; Middle Aged; Prospective Studies; Renal Dialysis

2012
Chronic use of sodium ferric gluconate complex in hemodialysis patients: safety of higher-dose (> or =250 mg) administration.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 2003, Volume: 41, Issue:3

    Topics: Anemia, Iron-Deficiency; Drug Administration Schedule; Female; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Humans; Infusions, Intravenous; Kidney Failure, Chronic; Male; Middle Aged; Peritoneal Dialysis; Population Surveillance; Treatment Outcome

2003
The effects of intravenous iron treatment on oxidant stress and erythrocyte deformability in hemodialysis patients.
    Scandinavian journal of urology and nephrology, 2003, Volume: 37, Issue:1

    Topics: Adult; Dose-Response Relationship, Drug; Erythrocyte Deformability; Female; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Humans; Infusions, Intravenous; Injections, Intravenous; Iron; Kidney Failure, Chronic; Male; Middle Aged; Oxidative Stress; Renal Dialysis; Sucrose; Time Factors

2003
High-dose parenteral iron sucrose depresses neutrophil intracellular killing capacity.
    Kidney international, 2003, Volume: 64, Issue:2

    Topics: Anemia; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Humans; Injections, Intravenous; Kidney Failure, Chronic; Neutrophils; Peritoneal Dialysis; Phagocytosis; Prospective Studies; Respiratory Burst

2003
The safety and efficacy of an accelerated iron sucrose dosing regimen in patients with chronic kidney disease.
    Kidney international. Supplement, 2003, Issue:87

    Topics: Aged; Anemia; Blood Pressure; Female; Ferric Compounds; Ferric Oxide, Saccharated; Ferritins; Glucaric Acid; Humans; Infusions, Intravenous; Kidney Failure, Chronic; Male; Middle Aged; Prospective Studies; Transferrin; Treatment Outcome

2003
Iron sucrose in hemodialysis patients: safety of replacement and maintenance regimens.
    Kidney international, 2004, Volume: 66, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Anemia; Drug Hypersensitivity; Female; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Humans; Kidney Failure, Chronic; Male; Middle Aged; Renal Dialysis; Sepsis

2004
Parenteral iron therapy in treatment of anemia in end-stage renal disease patients: a comparative study between iron saccharate and gluconate.
    Nephron. Clinical practice, 2005, Volume: 99, Issue:4

    Topics: Adult; Anemia, Iron-Deficiency; Female; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Gluconates; Humans; Kidney Failure, Chronic; Male; Parenteral Nutrition; Renal Dialysis

2005
Intravenous iron increases labile serum iron but does not impair forearm blood flow reactivity in dialysis patients.
    Kidney international, 2005, Volume: 68, Issue:6

    Topics: Adult; Aged; Anemia; Female; Ferric Compounds; Ferric Oxide, Saccharated; Forearm; Glucaric Acid; Humans; Injections, Intravenous; Kidney Failure, Chronic; Male; Middle Aged; Oxidative Stress; Peritoneal Dialysis; Prospective Studies; Regional Blood Flow; Vasodilation

2005
Comparison of oxidative stress markers after intravenous administration of iron dextran, sodium ferric gluconate, and iron sucrose in patients undergoing hemodialysis.
    Pharmacotherapy, 2007, Volume: 27, Issue:3

    Topics: Biomarkers; Cross-Over Studies; Female; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Humans; Infusions, Intravenous; Iron-Dextran Complex; Kidney Failure, Chronic; Lipid Peroxidation; Male; Middle Aged; Oxidative Stress; Prospective Studies; Renal Dialysis

2007
Administration of exogenous erythropoietin beta affects lipid peroxidation and serum paraoxonase-1 activity and concentration in predialysis patients with chronic renal disease and anaemia.
    Clinical and experimental pharmacology & physiology, 2007, Volume: 34, Issue:4

    Topics: Aged; Anemia; Antibodies; Aryldialkylphosphatase; Dose-Response Relationship, Drug; Erythropoietin; Female; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Hemoglobins; Humans; Injections, Intravenous; Injections, Subcutaneous; Kidney Failure, Chronic; Lipid Peroxidation; Lipoproteins, LDL; Male; Middle Aged; Oxidative Stress; Recombinant Proteins; Renal Dialysis; Treatment Outcome

2007
Is there a difference between the allergic potencies of the iron sucrose and low molecular weight iron dextran?
    Renal failure, 2007, Volume: 29, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Anemia; Female; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Hematinics; Humans; Infusions, Intra-Arterial; Iron-Dextran Complex; Kidney Failure, Chronic; Male; Middle Aged

2007
Optimum dosage regimen for iron sucrose.
    Kidney international, 2007, Volume: 72, Issue:2

    Topics: Adult; Aged; Anemia, Iron-Deficiency; Female; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Humans; Kidney Failure, Chronic; Male; Middle Aged; Treatment Outcome

2007
Slow intravenous iron administration does not aggravate oxidative stress and inflammatory biomarkers during hemodialysis: a comparative study between iron sucrose and iron dextran.
    American journal of nephrology, 2007, Volume: 27, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Anemia, Iron-Deficiency; Biomarkers; C-Reactive Protein; Female; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Hematinics; Humans; Inflammation Mediators; Infusions, Intravenous; Interleukin-6; Iron-Dextran Complex; Kidney Failure, Chronic; Lipoproteins, LDL; Male; Middle Aged; Oxidative Stress; Renal Dialysis; Serum Albumin; Tumor Necrosis Factor-alpha

2007
Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia.
    Blood purification, 2008, Volume: 26, Issue:2

    Topics: Adult; Aged; Anemia; China; Drug Therapy, Combination; Erythropoietin; Female; Ferric Compounds; Ferric Oxide, Saccharated; Ferrous Compounds; Glucaric Acid; Hemoglobins; Humans; Iron; Kidney Failure, Chronic; Male; Middle Aged; Recombinant Proteins; Renal Dialysis; Treatment Outcome

2008
Intravenous ferric saccharate as an iron supplement in dialysis patients.
    Nephron, 1996, Volume: 72, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Anemia; Drug Combinations; Erythropoietin; Female; Ferric Compounds; Ferric Oxide, Saccharated; Ferritins; Glucaric Acid; Humans; Injections, Intravenous; Iron; Kidney Failure, Chronic; Male; Middle Aged; Peritoneal Dialysis, Continuous Ambulatory; Prospective Studies; Renal Dialysis

1996
Safety of intravenous injection of iron saccharate in haemodialysis patients.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 1996, Volume: 11, Issue:9

    Topics: Adult; Aged; Drug Tolerance; Erythropoietin; Female; Ferric Compounds; Ferric Oxide, Saccharated; Ferritins; Glucaric Acid; Humans; Injections, Intravenous; Iron; Kidney Failure, Chronic; Kinetics; Male; Middle Aged; Recombinant Proteins; Renal Dialysis; Transferrin

1996
The efficiency of fractionated parenteral iron treatment in CAPD patients.
    Advances in peritoneal dialysis. Conference on Peritoneal Dialysis, 1997, Volume: 13

    Topics: Adult; Anemia; Drug Administration Schedule; Drug Therapy, Combination; Erythropoietin; Female; Ferric Compounds; Ferric Oxide, Saccharated; Ferritins; Glucaric Acid; Hematocrit; Humans; Injections, Intravenous; Kidney Failure, Chronic; Male; Middle Aged; Organization and Administration; Peritoneal Dialysis, Continuous Ambulatory; Recombinant Proteins; Sucrose; Transferrin

1997
Iron supplementation in haemodialysis--practical clinical guidelines.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 1998, Volume: 13, Issue:10

    Topics: Anemia, Iron-Deficiency; Biomarkers; Drug Administration Routes; Erythropoietin; Female; Ferric Compounds; Ferric Oxide, Saccharated; Ferritins; Follow-Up Studies; Glucaric Acid; Hemoglobins; Humans; Iron; Iron Deficiencies; Kidney Failure, Chronic; Male; Middle Aged; Nutritional Support; Practice Guidelines as Topic; Prospective Studies; Recombinant Proteins; Renal Dialysis; Sucrose; Transferrin

1998
Catalytically active iron and bacterial growth in serum of haemodialysis patients after i.v. iron-saccharate administration.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2000, Volume: 15, Issue:11

    Topics: Adult; Aged; Bleomycin; Erythropoietin; Female; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Humans; Injections, Intravenous; Iron; Kidney Failure, Chronic; Male; Middle Aged; Recombinant Proteins; Renal Dialysis; Staphylococcus epidermidis; Transferrin

2000
Efficacy and safety of iron sucrose for iron deficiency in patients with dialysis-associated anemia: North American clinical trial.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 2001, Volume: 37, Issue:2

    Topics: Aged; Anemia, Iron-Deficiency; Epoetin Alfa; Erythrocyte Indices; Erythropoietin; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Hemoglobins; Humans; Injections, Intravenous; Iron; Kidney Failure, Chronic; Middle Aged; Prospective Studies; Recombinant Proteins; Renal Dialysis

2001
The effect of i.v. iron alone or in combination with low-dose erythropoietin in the rapid correction of anemia of chronic renal failure in the predialysis period.
    Clinical nephrology, 2001, Volume: 55, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Anemia; Drug Therapy, Combination; Erythropoietin; Female; Ferric Compounds; Ferric Oxide, Saccharated; Ferritins; Glucaric Acid; Hematocrit; Humans; Infusions, Intravenous; Injections, Subcutaneous; Kidney Failure, Chronic; Male; Middle Aged; Recombinant Proteins; Renal Dialysis; Sucrose

2001
Nontransferrin-bound iron in the plasma of haemodialysis patients after intravenous iron saccharate infusion.
    European journal of clinical investigation, 2002, Volume: 32 Suppl 1

    Topics: Anemia; Dialysis Solutions; Female; Ferric Compounds; Ferric Oxide, Saccharated; Ferritins; Glucaric Acid; Humans; Infusions, Intravenous; Iron; Kidney Failure, Chronic; Male; Protein Binding; Renal Dialysis; Transferrin

2002
Low-dose intravenous iron administration in chronic hemodialysis patients treated with recombinant human erythropoietin.
    Renal failure, 2002, Volume: 24, Issue:2

    Topics: Aged; Anemia; Dose-Response Relationship, Drug; Erythropoietin; Female; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Hematinics; Humans; Infusions, Intravenous; Kidney Failure, Chronic; Male; Middle Aged; Prospective Studies; Recombinant Proteins; Renal Dialysis

2002

Other Studies

39 other study(ies) available for glucaric acid and Kidney Failure, Chronic

ArticleYear
Zinc deficiency anaemia in haemodialysis patients: Often overlooked but a treatable cause of anaemia.
    Nephrology (Carlton, Vic.), 2017, Volume: 22, Issue:12

    Topics: Aged, 80 and over; Anemia; Biomarkers; Carnosine; Darbepoetin alfa; Deficiency Diseases; Female; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Hematinics; Hemoglobins; Humans; Kidney Failure, Chronic; Organometallic Compounds; Renal Dialysis; Treatment Outcome; Zinc; Zinc Compounds

2017
Influence of Carnicor, Venofer, and Sevelamer on the levels of genotoxic damage in end-stage renal disease patients.
    Environmental and molecular mutagenesis, 2018, Volume: 59, Issue:4

    Topics: Carnitine; Chelating Agents; Comet Assay; DNA Damage; Female; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Hematinics; Humans; Kidney Failure, Chronic; Lymphocytes; Male; Micronucleus Tests; Middle Aged; Neuroprotective Agents; Oxidative Stress; Sevelamer

2018
The influence of inflammatory markers and CRP predictive value in relation to the target hemoglobin level in patients on chronic hemodialysis.
    Medical archives (Sarajevo, Bosnia and Herzegovina), 2013, Volume: 67, Issue:5

    Topics: Aged; Anemia; Biomarkers; C-Reactive Protein; Case-Control Studies; Cross-Sectional Studies; Erythropoietin; Female; Ferric Compounds; Ferric Oxide, Saccharated; Ferritins; Fibrinogen; Glucaric Acid; Hemoglobins; Humans; Inflammation; Kidney Failure, Chronic; Male; Middle Aged; Predictive Value of Tests; Renal Dialysis; ROC Curve; Sucrose

2013
Comparative outcomes of predominant facility-level use of ferumoxytol versus other intravenous iron formulations in incident hemodialysis patients.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2015, Volume: 30, Issue:12

    Topics: Administration, Intravenous; Aged; Anemia; Female; Ferric Compounds; Ferric Oxide, Saccharated; Ferrosoferric Oxide; Glucaric Acid; Hematinics; Humans; Kidney Failure, Chronic; Male; Middle Aged; Myocardial Infarction; Prognosis; Proportional Hazards Models; Renal Dialysis; Renal Insufficiency, Chronic; Stroke; United States

2015
Performance of a Predictive Model for Long-Term Hemoglobin Response to Darbepoetin and Iron Administration in a Large Cohort of Hemodialysis Patients.
    PloS one, 2016, Volume: 11, Issue:3

    Topics: Aged; Anemia; Darbepoetin alfa; Disease Management; Erythropoiesis; Female; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Hematinics; Hemoglobins; Humans; Injections, Intravenous; Kidney Failure, Chronic; Male; Middle Aged; Models, Statistical; Neural Networks, Computer; Renal Dialysis; Retrospective Studies

2016
Distinct in vitro Complement Activation by Various Intravenous Iron Preparations.
    American journal of nephrology, 2017, Volume: 45, Issue:1

    Topics: Administration, Intravenous; Anemia, Iron-Deficiency; Complement Activation; Complement C1q; Complement C3d; Complement Membrane Attack Complex; Disaccharides; Ferric Compounds; Ferric Oxide, Saccharated; Ferrosoferric Oxide; Glucaric Acid; Hematinics; Humans; In Vitro Techniques; Iron Compounds; Iron-Dextran Complex; Kidney Failure, Chronic; Maltose; Mannose-Binding Lectin; Properdin; Renal Dialysis

2017
Safety of Intravenous Iron in Hemodialysis: Longer-term Comparisons of Iron Sucrose Versus Sodium Ferric Gluconate Complex.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 2017, Volume: 69, Issue:6

    Topics: Administration, Intravenous; Aged; Anemia; Cardiovascular Diseases; Cause of Death; Female; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Hematinics; Humans; Infections; Kidney Failure, Chronic; Male; Middle Aged; Mortality; Proportional Hazards Models; Renal Dialysis; Retrospective Studies

2017
Intravenous iron sucrose does not impair sonographic brachial vasodilation in peritoneal dialysis patients.
    Advances in peritoneal dialysis. Conference on Peritoneal Dialysis, 2008, Volume: 24

    Topics: Brachial Artery; Endothelium, Vascular; Female; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Humans; Infusions, Intravenous; Kidney Failure, Chronic; Male; Middle Aged; Peritoneal Dialysis; Ultrasonography; Vasodilation

2008
Parenteral iron use: possible contribution to exceeding target hemoglobin in hemodialysis patients.
    Clinical journal of the American Society of Nephrology : CJASN, 2009, Volume: 4, Issue:3

    Topics: Aged; Anemia, Iron-Deficiency; Centers for Medicare and Medicaid Services, U.S.; Drug Therapy, Combination; Female; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Hematinics; Hemoglobins; Humans; Injections, Intravenous; Iron-Dextran Complex; Kidney Failure, Chronic; Male; Middle Aged; Odds Ratio; Practice Guidelines as Topic; Renal Dialysis; Retrospective Studies; Risk Assessment; Time Factors; Treatment Outcome; United States

2009
The importance of iron in long-term survival of maintenance hemodialysis patients treated with epoetin-alfa and intravenous iron: analysis of 9.5 years of prospectively collected data.
    BMC nephrology, 2009, Feb-26, Volume: 10

    Topics: Adult; Aged; Anemia; Comorbidity; Drug Therapy, Combination; Epoetin Alfa; Erythropoietin; Female; Ferric Compounds; Ferric Oxide, Saccharated; Ferritins; Glucaric Acid; Hemoglobins; Humans; Infusions, Intravenous; Iron-Dextran Complex; Kaplan-Meier Estimate; Kidney Failure, Chronic; Male; Middle Aged; Proportional Hazards Models; Prospective Studies; Recombinant Proteins; Renal Dialysis; Retrospective Studies; Survival Analysis; Transferrin

2009
A pilot evaluation of the long-term effect of combined therapy with intravenous iron sucrose and erythropoietin in elderly patients with advanced chronic heart failure and cardio-renal anemia syndrome: influence on neurohormonal activation and clinical ou
    Journal of cardiac failure, 2009, Volume: 15, Issue:9

    Topics: Aged; Aged, 80 and over; Anemia; Chronic Disease; Cohort Studies; Drug Evaluation; Drug Therapy, Combination; Erythropoietin; Female; Ferric Compounds; Ferric Oxide, Saccharated; Follow-Up Studies; Glucaric Acid; Heart Failure; Humans; Infusions, Intravenous; Kidney Failure, Chronic; Male; Neurotransmitter Agents; Pilot Projects; Prospective Studies; Recombinant Proteins; Survival Rate; Syndrome; Time Factors; Treatment Outcome

2009
Labile plasma iron generation after intravenous iron is time-dependent and transitory in patients undergoing chronic hemodialysis.
    Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy, 2010, Volume: 14, Issue:2

    Topics: Aged; Aged, 80 and over; Female; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Hematinics; Humans; Infusions, Intravenous; Iron; Kidney Failure, Chronic; Male; Middle Aged; Renal Dialysis; Time Factors

2010
[Treatment with intravenous iron and ferritin level].
    Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia, 2010, Volume: 30, Issue:3

    Topics: Anemia; Blood Proteins; Case-Control Studies; Clinical Protocols; Drug Monitoring; Erythropoiesis; Erythropoietin; Ferric Compounds; Ferric Oxide, Saccharated; Ferritins; Glucaric Acid; Humans; Infusions, Intravenous; Kidney Failure, Chronic; Oxidation-Reduction; Prospective Studies; Renal Dialysis

2010
Influence of intravenous iron therapy on novel markers of iron deficiency.
    The International journal of artificial organs, 2010, Volume: 33, Issue:5

    Topics: Anemia, Iron-Deficiency; Biomarkers; Cross-Sectional Studies; Female; Ferric Compounds; Ferric Oxide, Saccharated; Ferritins; Glucaric Acid; Hematinics; Hemoglobins; Humans; Infusions, Intravenous; Kidney Failure, Chronic; Male; Middle Aged; Predictive Value of Tests; Prospective Studies; Renal Dialysis; Reticulocytes; Time Factors; Transferrin; Treatment Outcome

2010
The influence of need-based, continuous, low-dose iron replacement on hemoglobin levels in hemodialysis patients treated with erythropoiesis-stimulating agents.
    Artificial organs, 2011, Volume: 35, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Anemia; Female; Ferric Compounds; Ferric Oxide, Saccharated; Ferritins; Glucaric Acid; Hematinics; Hemoglobins; Humans; Kidney Failure, Chronic; Male; Middle Aged; Renal Dialysis

2011
Total dose infusion of intravenous iron in patients with chronic kidney disease receiving haemodialysis.
    Journal of renal care, 2011, Volume: 37, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Anemia, Iron-Deficiency; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Humans; Infusions, Intravenous; Kidney Failure, Chronic; Middle Aged; Renal Dialysis; Young Adult

2011
Comparison of adverse-event profiles of intravenous low-molecular-weight iron dextran and iron sucrose in peritoneal dialysis patients.
    Renal failure, 2011, Volume: 33, Issue:3

    Topics: Adult; Aged; Anemia; Dextrans; Female; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Hematinics; Humans; Infusions, Intravenous; Kidney Failure, Chronic; Male; Middle Aged; Peritoneal Dialysis

2011
Effect of intravenous saccharated ferric oxide on serum FGF23 and mineral metabolism in hemodialysis patients.
    American journal of nephrology, 2011, Volume: 33, Issue:5

    Topics: Aged; Female; Ferric Compounds; Ferric Oxide, Saccharated; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Glucaric Acid; Humans; Infusions, Intravenous; Kidney Failure, Chronic; Male; Middle Aged; Parathyroid Glands; Parathyroid Hormone; Phosphates; Prospective Studies; Renal Dialysis; Vitamin D

2011
Iron sucrose impairs phagocytic function and promotes apoptosis in polymorphonuclear leukocytes.
    American journal of nephrology, 2012, Volume: 36, Issue:1

    Topics: Adult; Anemia; Apoptosis; Carbohydrates; Escherichia coli; Female; Ferric Compounds; Ferric Oxide, Saccharated; Flow Cytometry; Glucaric Acid; Hematinics; Humans; Kidney Failure, Chronic; Male; Neutrophils; Phagocytosis; Staphylococcus aureus; Time Factors

2012
Changing patterns of anemia management in US hemodialysis patients.
    The American journal of medicine, 2012, Volume: 125, Issue:9

    Topics: Adolescent; Adult; Aged; Anemia; Child; Child, Preschool; Erythropoietin; Female; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Hematinics; Hemoglobins; Humans; Infusions, Intravenous; Iron Compounds; Kidney Failure, Chronic; Male; Middle Aged; Practice Patterns, Physicians'; Renal Dialysis; Time Factors; United States

2012
The correction of anemia in severe resistant heart failure with erythropoietin and intravenous iron prevents the progression of both the heart and the renal failure and markedly reduces hospitalization.
    Clinical nephrology, 2002, Volume: 58 Suppl 1

    Topics: Aged; Anemia; Disease Progression; Drug Therapy, Combination; Erythropoietin; Female; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Heart Failure; Hospitalization; Humans; Injections, Intravenous; Injections, Subcutaneous; Kidney Failure, Chronic; Male; Oxygen Consumption; Recombinant Proteins; Stroke Volume

2002
[Changes in iron metabolism and erythropoietin requirements after the switch from ferric gluconate to iron saccharose. Is it worth the increased expense?].
    Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia, 2003, Volume: 23, Issue:2

    Topics: Aged; Aged, 80 and over; Anemia; Cost-Benefit Analysis; Drug Costs; Erythropoietin; Female; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Humans; Iron; Kidney Failure, Chronic; Male; Middle Aged; Renal Dialysis; Spain; Sucrose

2003
Intravenous iron therapy in chronic kidney disease and peritoneal dialysis patients.
    Nephrology nursing journal : journal of the American Nephrology Nurses' Association, 2003, Volume: 30, Issue:5

    Topics: Anemia, Iron-Deficiency; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Hematinics; Humans; Infusions, Intravenous; Iron; Iron-Dextran Complex; Kidney Failure, Chronic; Peritoneal Dialysis

2003
The use of androgens in anaemia resistant to erythropoietin and i.v. iron in patients with heart and renal failure.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2004, Volume: 19, Issue:4

    Topics: Aged; Anemia; Female; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Heart Failure; Humans; Injections, Intravenous; Kidney Failure, Chronic; Male; Nandrolone; Nandrolone Decanoate; Sucrose

2004
Elevated cardiac troponin T in hemodialysis patients receiving more intravenous iron sucrose.
    Renal failure, 2004, Volume: 26, Issue:6

    Topics: Adolescent; Adult; Age Distribution; Aged; Aged, 80 and over; Biomarkers; Blood Chemical Analysis; Case-Control Studies; Chi-Square Distribution; Combined Modality Therapy; Coronary Artery Disease; Disease Progression; Dose-Response Relationship, Drug; Female; Ferric Compounds; Ferric Oxide, Saccharated; Follow-Up Studies; Glucaric Acid; Humans; Incidence; Infusions, Intravenous; Kidney Failure, Chronic; Kidney Function Tests; Male; Middle Aged; Prospective Studies; Reference Values; Renal Dialysis; Risk Assessment; Sensitivity and Specificity; Severity of Illness Index; Sex Distribution; Statistics, Nonparametric; Survival Rate; Treatment Outcome; Troponin T

2004
[Comparison of intravenous ascorbic acid versus intravenous iron for functional iron deficiency in hemodialysis patients].
    Nihon Jinzo Gakkai shi, 2004, Volume: 46, Issue:8

    Topics: Aged; Anemia, Iron-Deficiency; Ascorbic Acid; Biomarkers; Female; Ferric Compounds; Ferric Oxide, Saccharated; Ferritins; Glucaric Acid; Humans; Iron; Kidney Failure, Chronic; Male; Middle Aged; Renal Dialysis; Retrospective Studies; Treatment Outcome

2004
Combination of intravenous iron sucrose and ascorbic acid in hemodialysis patients.
    Kidney international, 2005, Volume: 68, Issue:1

    Topics: Anemia; Antioxidants; Ascorbic Acid; Drug Therapy, Combination; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Humans; Injections, Intravenous; Kidney Failure, Chronic; Renal Dialysis

2005
Trends in intravenous iron use among dialysis patients in the United States (1994-2002).
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 2005, Volume: 46, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anemia, Hypochromic; Child; Child, Preschool; Drug Utilization; Erythropoietin; Female; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Humans; Incidence; Infant; Infusions, Intravenous; Kidney Failure, Chronic; Male; Medicare; Middle Aged; Outpatients; Peritoneal Dialysis; Prevalence; Recombinant Proteins; Renal Dialysis; Retrospective Studies; United States

2005
Relationship between iron replacement and hepatic functions in hepatitis C virus-positive chronic haemodialysis patients.
    Nephrology (Carlton, Vic.), 2005, Volume: 10, Issue:5

    Topics: Adolescent; Adult; Aged; Alanine Transaminase; Anemia; Female; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Hepatic Insufficiency; Hepatitis C, Chronic; Humans; Injections, Intravenous; Kidney Failure, Chronic; Liver; Male; Middle Aged; Renal Dialysis; Retrospective Studies

2005
Low incidence of adverse events following 90-minute and 3-minute infusions of intravenous iron sucrose in children on erythropoietin.
    Acta paediatrica (Oslo, Norway : 1992), 2005, Volume: 94, Issue:12

    Topics: Anemia; Child; Erythropoietin; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Humans; Infusions, Intravenous; Kidney Failure, Chronic; Prospective Studies; Recombinant Proteins

2005
Proinflammatory effects of iron sucrose in chronic kidney disease.
    Kidney international, 2006, Volume: 69, Issue:7

    Topics: Aged; Chemokine CCL2; Chronic Disease; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Humans; Inflammation; Kidney Diseases; Kidney Failure, Chronic; Reproducibility of Results

2006
Is i.v. iron really superior in CKD patients not on dialysis?
    Kidney international, 2006, Volume: 70, Issue:6

    Topics: Administration, Oral; Dose-Response Relationship, Drug; Ferric Compounds; Ferric Oxide, Saccharated; Follow-Up Studies; Glucaric Acid; Humans; Hypotension; Injections, Intravenous; Kidney Failure, Chronic; Randomized Controlled Trials as Topic; Time Factors; Treatment Outcome

2006
Association of different intravenous iron preparations with risk of bacteremia in maintenance hemodialysis patients.
    Clinical nephrology, 2006, Volume: 66, Issue:5

    Topics: Aged; Anemia, Iron-Deficiency; Bacteremia; Chi-Square Distribution; Dose-Response Relationship, Drug; Female; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Hematinics; Humans; Injections, Intravenous; Kidney Failure, Chronic; Male; Middle Aged; Poisson Distribution; Renal Dialysis; Retrospective Studies; Risk Assessment; Risk Factors; Statistics, Nonparametric

2006
Coronary artery vasospasm with iron sucrose.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2007, Volume: 22, Issue:6

    Topics: Coronary Vasospasm; Female; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Humans; Infusions, Intravenous; Kidney Failure, Chronic; Middle Aged; Myocardial Ischemia

2007
The safety of intravenous iron sucrose use in the elderly patient.
    The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists, 2007, Volume: 22, Issue:3

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anemia, Iron-Deficiency; Erythropoietin; Female; Ferric Compounds; Ferric Oxide, Saccharated; Geriatrics; Glucaric Acid; Hematinics; Humans; Injections, Intravenous; Kidney Failure, Chronic; Male; Middle Aged; Renal Dialysis

2007
Intravenous iron supplementation for the treatment of the anemia of moderate to severe chronic renal failure patients not receiving dialysis.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 1996, Volume: 27, Issue:2

    Topics: Administration, Oral; Adult; Aged; Anemia; Anemia, Iron-Deficiency; Delayed-Action Preparations; Erythropoietin; Female; Ferric Compounds; Ferric Oxide, Saccharated; Ferrous Compounds; Follow-Up Studies; Glucaric Acid; Humans; Injections, Intravenous; Kidney Failure, Chronic; Male; Middle Aged; Renal Dialysis; Time Factors

1996
Improved response to erythropoietin therapy with long-term continuous iron supplementation.
    Nephron, 2000, Volume: 84, Issue:2

    Topics: Anemia, Iron-Deficiency; Erythropoietin; Female; Ferric Compounds; Ferric Oxide, Saccharated; Ferritins; Glucaric Acid; Hemoglobins; Humans; Iron; Iron Overload; Kidney Failure, Chronic; Male; Middle Aged; Recombinant Proteins; Renal Dialysis

2000
Aggressive therapy of congestive heart failure and associated chronic renal failure with medications and correction of anemia stops or slows the progression of both diseases.
    Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis, 2001, Volume: 21 Suppl 3

    Topics: Aged; Anemia; Disease Progression; Drug Therapy, Combination; Erythropoietin; Female; Ferric Compounds; Ferric Oxide, Saccharated; Glomerular Filtration Rate; Glucaric Acid; Heart Failure; Humans; Kidney Failure, Chronic; Male; Recombinant Proteins; Stroke Volume; Sucrose

2001
Parenteral iron formulations: a comparative toxicologic analysis and mechanisms of cell injury.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 2002, Volume: 40, Issue:1

    Topics: Animals; Aorta; Cell Division; Cell Line; Cell Line, Transformed; Cell Survival; Chlorides; Endothelium, Vascular; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Humans; Iron; Iron-Dextran Complex; Kidney Failure, Chronic; Kidney Tubules, Proximal; Lipid Peroxidation; Male; Malondialdehyde; Mice; Oligosaccharides; Oxidants; Parenteral Nutrition

2002